Just out of curiosity. They've gone higher than seems necessary with their efficacy target. Why would they have done that? They could easily not meet their target and thus disappoint the market, but get results good enough to take the drug to production. Or am I reading it wrongly?
Just out of curiosity. They've gone higher than seems necessary...
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $175.8M | |||
| Open | High | Low | Value | Volume |
| 34.0¢ | 34.5¢ | 31.5¢ | $1.783M | 5.386M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 92430 | 31.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 94413 | 2 |
View Market Depth
| Last trade - 16.10pm 01/05/2024 (20 minute delay) ? |
|
|||||
|
Last
32.5¢ |
Change
-0.015 ( 2.99 %) |
||||
| Open | High | Low | Volume | ||
| 34.0¢ | 34.5¢ | 32.0¢ | 2631979 | ||
| Last updated 15.59pm 01/05/2024 ? | |||||
| DXB (ASX) Chart |